Cardlytics (CDLX) Prices 3.85M Share Common Offering at $130/Sh

Cardlytics, Inc. (NASDAQ: CDLX) today announced the pricing of an underwritten public offering of 3,850,000 shares of its common stock, at a price to the public of $130.00 per share. The gross proceeds to Cardlytics from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $500.5 million. The offering is expected to close on or about March 5, 2021, subject to customary closing conditions. In addition, Cardlytics has granted the underwriters a 30-day option to purchase up to an additional 577,500 shares of common stock at the public offering price, less underwriting discounts and commissions.

BofA Securities and J.P. Morgan are acting as joint book-running managers and representatives of the underwriters for the offering. Wells Fargo Securities is also acting as a book-running manager for the offering. Raymond James is acting as a manager for the offering.

The offering is being made pursuant to a shelf registration statement, including a base prospectus, filed by Cardlytics with the Securities and Exchange Commission (SEC), which was effective on March 1, 2021. The offering may be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement.

You May Also Be Interested In

• Definium Therapeutics plans $500M public share offering
• CervoMed closes $10M stock offering at $4.00 per share
• Dyne Therapeutics adds Barry Greene to its board of directors